- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Examining FMT for Patients With Recurrent C Difficile infections
The panelist discusses how fecal microbiota transplantation (FMT) involves transferring stool from healthy donors to restore gut microbiota in patients with recurrent Clostridioides difficile infection, though safety concerns include potential pathogen transmission and careful donor screening requirements, while OpenBiome’s standardized frozen FMT preparations have helped advance accessibility but should be used according to current FDA guidance for investigational use.
EP: 1.The Role of Testing for C Difficile in Clinical Practice
EP: 2.Utilizing Antibiotics in Treatment of C Difficile
EP: 3.Examining FMT for Patients With Recurrent C Difficile infections
EP: 4.Exploring Rebyota for Recurrent C Difficile Infections
EP: 5.Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections
EP: 6.Vowst as a Potential Option for Patients With Recurrent C Difficile Infections
EP: 7.Management of Recurrent C Difficile Infections in the Future
EP: 8.Key Background Information on Recurrent C. Difficile Infections
EP: 9.Importance of Early Detection of Recurrent C Difficile Infections
EP: 10.Impact of Recurrent C Difficile Infection on Costs and Patient Quality of Life
EP: 11.Diagnosis of Recurrent C Difficile Infections
EP: 12.Common Comorbidities Associated With Recurrent C Difficile Infections
EP: 13.Unmet Needs With Recurrent C Difficile Infections
Video content above is prompted by the following:
- Describe how FMT works and for which patients this can be used.
- What has recent data shown about the efficacy of FMT in preventing recurrent C difficile?
- What are the safety concerns when using FMT?
- Discuss the recent updates of an investigational FMT therapy from OpenBiome, and how this impacts your clinical decision-making.
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
